Literature DB >> 2848928

Fine mapping of the major latency-related RNA of herpes simplex virus type 1 in humans.

S L Wechsler1, A B Nesburn, R Watson, S Slanina, H Ghiasi.   

Abstract

In situ hybridization with synthetic oligonucleotides was used to fine map the extent and continuity of herpes simplex virus type 1 (HSV-1) latency-related RNA (LR RNA) in trigeminal ganglia of latently infected humans. A series of 34 20 residue oligonucleotides were employed to cover a 3 kb region of the HSV-1 genome to which the latency-related gene had previously been mapped. The 5' end of the main LR RNA transcript began approximately 1210 nucleotides downstream from the 3' end of the mRNA from the immediate early gene ICP0. The 3' end of the LR RNA overlapped the 3' end of the ICP0 mRNA by approximately 1000 nucleotides. A potential small intron was detected near the 3' end of the LR RNA.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2848928     DOI: 10.1099/0022-1317-69-12-3101

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  51 in total

1.  Enhancer and long-term expression functions of herpes simplex virus type 1 latency-associated promoter are both located in the same region.

Authors:  H Berthomme; J Thomas; P Texier; A Epstein; L T Feldman
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

2.  Localization of cis-acting sequence requirements in the promoter of the latency-associated transcript of herpes simplex virus type 1 required for cell-type-specific activity.

Authors:  A H Batchelor; P O'Hare
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

3.  Herpes Simplex Virus 1 ICP22 Suppresses CD80 Expression by Murine Dendritic Cells.

Authors:  Harry Matundan; Homayon Ghiasi
Journal:  J Virol       Date:  2019-01-17       Impact factor: 5.103

Review 4.  Herpes simplex virus ocular infections: current concepts of acute, latent and reactivated disease.

Authors:  D Pavan-Langston
Journal:  Trans Am Ophthalmol Soc       Date:  1990

5.  Identical 371-base-pair deletion mutations in the LAT genes of herpes simplex virus type 1 McKrae and 17syn+ result in different in vivo reactivation phenotypes.

Authors:  J M Loutsch; G C Perng; J M Hill; X Zheng; M E Marquart; T M Block; H Ghiasi; A B Nesburn; S L Wechsler
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

6.  Activity of herpes simplex virus type 1 latency-associated transcript (LAT) promoter in neuron-derived cells: evidence for neuron specificity and for a large LAT transcript.

Authors:  J C Zwaagstra; H Ghiasi; S M Slanina; A B Nesburn; S C Wheatley; K Lillycrop; J Wood; D S Latchman; K Patel; S L Wechsler
Journal:  J Virol       Date:  1990-10       Impact factor: 5.103

7.  Herpes simplex virus type 1 latency-associated transcription plays no role in establishment or maintenance of a latent infection in murine sensory neurons.

Authors:  F Sedarati; K M Izumi; E K Wagner; J G Stevens
Journal:  J Virol       Date:  1989-10       Impact factor: 5.103

8.  The latency-associated transcript gene of herpes simplex virus type 1 (HSV-1) is required for efficient in vivo spontaneous reactivation of HSV-1 from latency.

Authors:  G C Perng; E C Dunkel; P A Geary; S M Slanina; H Ghiasi; R Kaiwar; A B Nesburn; S L Wechsler
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

9.  The role of neutralizing antibody and T-helper subtypes in protection and pathogenesis of vaccinated mice following ocular HSV-1 challenge.

Authors:  H Ghiasi; S L Wechsler; S Cai; A B Nesburn; F M Hofman
Journal:  Immunology       Date:  1998-11       Impact factor: 7.397

10.  Herpes Simplex Virus 1 Latency and the Kinetics of Reactivation Are Regulated by a Complex Network of Interactions between the Herpesvirus Entry Mediator, Its Ligands (gD, BTLA, LIGHT, and CD160), and the Latency-Associated Transcript.

Authors:  Shaohui Wang; Alexander V Ljubimov; Ling Jin; Klaus Pfeffer; Mitchell Kronenberg; Homayon Ghiasi
Journal:  J Virol       Date:  2018-11-27       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.